Mechanism of cardiotoxicity of halofantrine

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 5, 2000, Pages 521-529

  Wesche, David L ^b   Schuster, Brian G ^b   Wang, Wen Xiu ^b   Woosley, Raymond L ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; HALOFANTRINE;

ADULT; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; DRUG MECHANISM; ELECTROCARDIOGRAM; FEMALE; HEART REPOLARIZATION; HUMAN; MALE; PRIORITY JOURNAL; QT INTERVAL; STEREOCHEMISTRY; STEREOISOMERISM;

EID: 0001403852     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.106127     Document Type: Article

References (27)

1. 1. Olliaro P, Cattani J, Wirth D. Malaria, the submerged disease. JAMA 1996;275:230-3.
2. 2. Milton KA, Edwards G, Ward SA, Orme ML, Breckenridge AM. Pharmacokinetics of halofantrine in man: effects of food and dose size. Br J Clin Pharmacol 1989; 28:71-7.
3. 3. Shanks GD, Watt G, Edstein MD, Webster HK, Loesuttiviboon L, Wechgritaya S. Halofantrine given with food for falciparum malaria. Trans R Soc Trop Med Hyg 1992; 86:233-4.
4. 4. Ohrt C, Watt G, Teja-Isavadharm P, Keeratithakul D, Loesuttiviboon L, Webster HK, et al. Pharmacokinetics of an extended-dose halofantrine regimen in patients with malaria and in healthy volunteers. Clin Pharmacol Ther 1995;57:525-32.
5. 5. ter Kuile FO, Dolan G, Nosten F, Edstein MD, Luxemburger C, Phaipun L, et al. Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet 1993;341:1044-9.
6. 6. Schuster BG, Canfield CJ. Preclinical studies with halofantrine. Parasitol Today 1989;5(suppl):3-14.
7. 7. Nosten F, ter Kuile FO, Luxemburger C, Woodrow C, Kyle DE, Chongsuphajaisiddhi T, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet 1993; 341:1054-6.
8. 8. Karbwang J, Na Bangchang K, Bunnag D, Harinasuta T, Laothavom P. Cardiac effect of halofantrine. Lancet 1993; 342:501.
9. 9. Castot A, Rapoport P, Le Coz P. Prolonged QT interval with halofantrine. Lancet 1993;341:1541.
10. 10. Monlun E, Pillet O, Cochard JF, Favarel Garrigues JC, Le Bras M. Prolonged QT interval with halofantrine. Lancet 1993;341:1541-2.
11. 11. Fourcade L, Hovette P, De Pina JJ, Rault JP, Peyron F, Touze JE. Prolonged QT interval and cardiac toxicity due to halofantrine [letter]. Med Trop (Mars) 1995;55:182-3.
12. 12. Toivonen L, Viitasalo M, Siikamaki H, Raatikka M, Pohjola-Sintonen S. Provocation of ventricular tachycardia by antimalarial drug halofantrine in congenital long QT syndrome. Clin Cardiol 1994;17:403-4.
13. 13. Monlun E, Le Metayer P, Szwandt S, Neau D, Longy-Boursier M, Horton J, et al. Cardiac complications of halofantrine: a prospective study of 20 patients. Trans R Soc Trop Med Hyg 1995;89:430-3.
14. 14. World Health Organization. Drug alert: halofantrine. Wkly Epidemiol Rec 1993;68:269-70.
15. 15. Kessler DA. Introducing MEDWatch: a new approach to reporting medication and device adverse effects and product problems. JAMA 1993;269:2765-8.
16. 16. Drici MD, Burklow TR, Haridasse V, Glazer RI, Woosley RL. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation 1996;94:1471-4.
17. 17. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of cardiotoxic actions of terfenadine. JAMA 1993;269: 1532-6.
18. 18. Hamill OP, Marty A, Neher E, Sakmann S, Sigworth FJ. Improved patch clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 1981;391:85-100.
19. 19. Morganroth J. Relations of QTc prolongation on the electrocardiogram to torsades de pointes: definitions and mechanisms. Am J Cardiol 1993;72:10B-3B.
20. 20. Tan HL, Hou CJY, Lauer MR, Sung RJ. Electrophysiologic mechanisms of the long QT interval syndromes and torsades de pointes. Ann Intern Med 1995;122:701-14.
21. 21. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. Clin Cardiol 1993;270:2590-7.
22. 22. Monlun E, Leenhardt A, Pillet O, Gaston R, Receveur MC, Bouabdallah K, et al. [Ventricular arrhythmia and halofantrine intake. Probable deleterious effect. Apropos of 3 cases]. Bull Soc Pathol Exot 1993;86:365-7.
23. 23. Basco LK, Gillotin C, Gimenez F, Farinotti R, Le Bras J. Activity in vitro of the enantiomers of halofantrine. Trans R Soc Trop Med Hyg 1993;87:78-9.
24. 24. Gimenez F, Aubry AF, Farinotti R, Kirkland K, Wainer IW. The determination of the enantiomers of halofantrine and mono N-desbutylhalofantrine in plasma and whole blood using sequential achiral/chiral high-performance liquid chromatography. J Pharm Biomed Anal 1992;10:245-50.
25. 25. Touze JE, Bernard J, Keundjian A, Imbert P, Viguier A, Chaudet H, et al. Electrocardiographic changes and halofantrine plasma level during acute falciparum malaria. Am J Trop Med Hyg 1996;54:225-228.
26. 26. Basco LK, Gillotin C, Gimenez F, Farinotti R, Le Bras J. Antimalarial activity in vitro of the N-desbutyl derivative of halofantrine. Trans R Soc Trop Med Hyg 1992; 86:12-3.
27. 27. AkhtarT, Imran M. Sudden deaths while on halofantrine treatments - a report of two cases from peshawar. JPMA J Pak Med Assoc 1994;44:120-1.